Patient P-01668

Synthetic patientNBL-101 · Day 117 · 45–54 · F · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Improving

GI state

Unstable

Inflammatory state

Improving

Nutritional resilience

Unstable

Discontinuation risk

80%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 44 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 55 GI-04 recommended — GI Support Protocol GI-04
Day 56 Patient accepted — Started GI-04 in the companion
Day 64 No meaningful change — GI Support Protocol GI-04
Day 64 ME-01 recommended — Monitoring Escalation ME-01
Day 65 Patient accepted — Started ME-01 in the companion
Day 68 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 44.

Primary contributors, last 14 days

Inflammatory activity-11
Nutritional resilience-8
Toxicity-6
GI instability+3

What helped?

GI Support Protocol GI-04Day 55
Result: no meaningful change
Monitoring Escalation ME-01Day 64
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Dietary Support Protocol NP-02

57%

probability of meaningful tolerance improvement

284 similar trajectories
66% showed improvement
median effect visible after 10 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 67 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 37/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 58
Drug metabolism and exposure ↑20
- BloodToxicity index 47
Autonomic recovery ↓20
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.8 · butyrate capacity 37/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 51 ms
Sleep: 6.4 h
Steps: 3,996
Resting HR: 68 bpm

Daily log: GI score 67, nutritional resilience 31, adherence 46.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01531	52%	S14	ME-01	improved	51
P-01842	52%	S14	NP-02	improved	55
P-01412	47%	S14	NP-02	improved	49
P-01511	46%	S14	GI-04	improved	65
P-01647	46%	S14	GI-04	improved	64
P-01598	45%	S14	GI-04	no change	45
P-01720	45%	S14	NP-02	improved	47
P-01743	45%	S14	SC-12	no change	52
P-01845	45%	S14	NP-02	improved	47
P-01581	44%	S18	GI-04	improved	51
P-01612	44%	S14	ME-01	improved	51
P-01615	44%	S14	ME-01	improved	48